THIO has received 2 prior orphan drug designations, and the agent has shown promise in preclinical studies for the treatment of glioblastoma.
THIO has been granted an ODD from the FDA for treatment of glioblastoma, according to MAIA Biotechnology, THIO’s manufacturer.1 The ODD designation provides incentives to make drug development for rare diseases more attainable, including up to 7 years of market exclusivity and tax credits.2
THIO is a first-in-class small molecule cancer telomere-targeting agent, and data presented to the FDA demonstrated that THIO could successfully penetrated the blood brain barrier in syngeneic and humanized murine models of telomerase-expressing brain cancers.
“Treatment with THIO resulted in potent anticancer activity and significant expansion of the animal lifespan for several difficult to treat cell lines and xenograft mouse models,” said Sergei Gryaznov, PhD, chief scientific officer of MAIA Biotechnology, in a press release.1 “These results stem from THIO’s remarkable mechanism of action and its BBB penetrating property that allows for direct targeting of brain tumors in vivo and potentially in glioblastoma patients.”
In 2022, THIO was granted ODDs for treatment of HCC and SCLC.
An ongoing phase 2, open-label, multicenter trial (NCT05208944) of THIO is enrolling and evaluating the agent in patients with advanced non–small cell lung cancer (NSCLC). The trial has an estimated enrollment of 182 patients.3
Part A is a safety lead-in group with a modified 3+3 design. Patients in this arm are being treated with a total of 180mg or 360 mg of THIO plus 350 mg of cemiplimab (Libtayo) per cycle. Patients in part B are receiving a total of 60 mg, 180 mg, or 360 mg of THIO plus 350 mg of cemiplimab per cycle. Patients in part C are receiving a total of 540 mg of THIO plus 350 mg of cemiplimab per cycle.
The primary end points are dose-limiting toxicities, treatment-emergent adverse events (AEs), serious AEs, overall response rate, and disease control rate. The secondary end points are duration of response, progression-free survival, and overall survival.
Patients with stage III or stage IV NSCLC who either progressed or relapsed after treatment with an immune checkpoint inhibitor, have an ECOG performance status of 0-1, and have adequate organ function are eligible to participate in the trial. Patients with untreated central nervous system metastases, active gastrointestinal bleeding, history of another concurrent malignancy, active infections requiring systemic therapy, or a condition requiring systemic treatment with immunosuppressive medication will be excluded from the study.
The trial has an estimated completion date of December 2024.3
“We are pleased to receive a third orphan drug designation for THIO, further highlighting FDA’s recognition of THIO’s potential in the treatment of multiple cancer indications, including rare ones such as glioblastoma,” said Vlad Vitoc, MD, chairman and chief executive office of MAIA Biotechnology, in a press release.1 “We consider this ODD an important milestone for our development strategy and for glioblastoma patients who could benefit from a potentially revolutionary therapy.”
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population
April 28th 2024During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Read More
Intracranial Response Data Supports Use of Brigatinib in ALK+ NSCLC
April 26th 2024During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed the intracranial efficacy of brigatinib from the ALTA-1L trial for patients with ALK+ non–small cell lung cancer in the first article of a 2-part series.
Read More